Survodutide SYNCHRONIZE Phase 3 — MASH primary endpoint design

Just got back from EASL and the survodutide data is genuinely practice-changing. The Phase 2b results showed 83% histological resolution of MASH at the highest dose (6mg), with 52% achieving fibrosis improvement by at least one stage without worsening of NASH. For those unfamiliar, survodutide is a dual GLP-1/glucagon receptor agonist from Boehringer Ingelheim. The glucagon component is the key differentiator here — it drives hepatic lipid oxidation and reduces de novo lipogenesis far more aggressively than GLP-1 alone. Key endpoints at 48 weeks (6mg dose): - MASH resolution without fibrosis worsening: 83.0% - Fibrosis improvement >=1 stage: 52.3% - Relative liver fat reduction (MRI-PDFF): -86.5% - ALT normalization: 76.2% Compare that to resmetirom (the only FDA-approved MASH therapy) at ~30% MASH resolution. We're in a different stratosphere. The GI tolerability was actually better than expected — nausea rates around 28% at 6mg, mostly transient during titration. Weight loss was substantial at ~18% from baseline, which tracks with the glucagon component's thermogenic effects. Any hepatologists here have thoughts on where this fits in the treatment landscape? I'm particularly interested in whether this could challenge liver biopsy as the standard for monitoring given how dramatic the imaging improvements are.